17 July 2026

Thalia Therapeutics plc

("Thalia" or the "Company")

AGM Statement

Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, will hold its Annual General Meeting ("AGM") today at 11.00 a.m. at the offices of Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.

Dr David Solomon, Chief Executive Officer, will provide the following statement:

"The past few months have marked a significant period in Thalia's evolution. Following our strategic repositioning as an RNA therapeutics company, the proposed acquisition of Sanmirna Therapeutics and the associated £2.75 million oversubscribed fundraise represent a transformational step, accelerating our transition into a clinical-stage biotechnology company and significantly strengthening our differentiated RNA therapeutics pipeline.

"Subject to shareholder approval today, the acquisition will add miRisten, a Phase 1 clinical-stage microRNA therapeutic for Acute Myeloid Leukaemia, alongside our proprietary Nuvec® delivery technology and our dual-targeting cardiovascular siRNA programme. Together, these create a diversified portfolio of innovative RNA therapeutics addressing significant unmet medical needs across oncology and cardiovascular disease, targeting multi-billion-dollar global markets.

"With funding in place for our planned work streams across the portfolio, including the completion of the Phase 1 clinical trial for miRisten, the Board believes Thalia is well positioned to deliver the next phase of its development and a number of important value-creating milestones. Our immediate priorities are to fully integrate Sanmirna following completion of the acquisition; complete the ongoing Phase 1 miRisten clinical study, which remains open and ongoing with patient enrolment temporarily paused while the current cohort progresses through the study, ahead of topline data expected in the first half of 2027 and subsequent preparation for Phase 2; advance our cardiovascular programme towards IND-enabling studies; and continue developing Nuvec® as a differentiated RNA delivery platform.

"Thalia is entering an exciting new phase of development and the Board would like to thank investors for their continued support. Subject to shareholder approval, we look forward to completing the acquisition and continuing to build a leading clinical-stage RNA therapeutics company. We remain focused on executing our strategy and look forward to updating the market as we advance our asset pipeline."

- Ends -

For more information please contact:

About Thalia Therapeutics plc

Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.

Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.

For further information visit www.thaliatx.com